Literature DB >> 12070033

Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.

Scott C Kogan1, Jerrold M Ward, Miriam R Anver, Jules J Berman, Cory Brayton, Robert D Cardiff, John S Carter, Sherri de Coronado, James R Downing, Torgny N Fredrickson, Diana C Haines, Alan W Harris, Nancy Lee Harris, Hiroshi Hiai, Elaine S Jaffe, Ian C M MacLennan, Pier Paolo Pandolfi, Paul K Pattengale, Archibald S Perkins, R Mark Simpson, Mark S Tuttle, Joanne F Wong, Herbert C Morse.   

Abstract

The hematopathology subcommittee of the Mouse Models of Human Cancers Consortium recognized the need for a classification of murine hematopoietic neoplasms that would allow investigators to diagnose lesions as well-defined entities according to accepted criteria. Pathologists and investigators worked cooperatively to develop proposals for the classification of lymphoid and nonlymphoid hematopoietic neoplasms. It is proposed here that nonlymphoid hematopoietic neoplasms of mice be classified in 4 broad categories: nonlymphoid leukemias, nonlymphoid hematopoietic sarcomas, myeloid dysplasias, and myeloid proliferations (nonreactive). Criteria for diagnosis and subclassification of these lesions include peripheral blood findings, cytologic features of hematopoietic tissues, histopathology, immunophenotyping, genetic features, and clinical course. Differences between murine and human lesions are reflected in the terminology and methods used for classification. This classification will be of particular value to investigators seeking to develop, use, and communicate about mouse models of human hematopoietic neoplasms.

Entities:  

Mesh:

Year:  2002        PMID: 12070033     DOI: 10.1182/blood.v100.1.238

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  214 in total

1.  Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia.

Authors:  Juraj Bies; Marek Sramko; Joanna Fares; Michael Rosu-Myles; Steven Zhang; Richard Koller; Linda Wolff
Journal:  Blood       Date:  2010-05-10       Impact factor: 22.113

2.  Preclinical efficacy of MEK inhibition in Nras-mutant AML.

Authors:  Michael R Burgess; Eugene Hwang; Ari J Firestone; Tannie Huang; Jin Xu; Johannes Zuber; Natacha Bohin; Tiffany Wen; Scott C Kogan; Kevin M Haigis; Deepak Sampath; Scott Lowe; Kevin Shannon; Qing Li
Journal:  Blood       Date:  2014-10-31       Impact factor: 22.113

3.  Associations of Autoimmunity, Immunodeficiency, Lymphomagenesis, and Gut Microbiota in Mice with Knockins for a Pathogenic Autoantibody.

Authors:  Shweta Jain; Jerrold M Ward; Dong-Mi Shin; Hongsheng Wang; Zohreh Naghashfar; Alexander L Kovalchuk; Herbert C Morse
Journal:  Am J Pathol       Date:  2017-07-17       Impact factor: 4.307

4.  A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency.

Authors:  Carl R Walkley; Gemma Haines Olsen; Sebastian Dworkin; Stewart A Fabb; Jeremy Swann; Grant A McArthur; Susan V Westmoreland; Pierre Chambon; David T Scadden; Louise E Purton
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

5.  Pathbase: a database of mutant mouse pathology.

Authors:  Paul N Schofield; Jonathan B L Bard; Catherine Booth; Jacques Boniver; Vincenzo Covelli; Philippe Delvenne; Michele Ellender; Wilhelm Engstrom; Wolfgang Goessner; Michael Gruenberger; Heinz Hoefler; John Hopewell; Mariatheresa Mancuso; Carmel Mothersill; Christopher S Potten; Leticia Quintanilla-Fend; Bjorn Rozell; Hannu Sariola; John P Sundberg; Andrew Ward
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

6.  Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Authors:  Hans-Guido Wendel; Elisa de Stanchina; Enriqué Cepero; Sagarika Ray; Michael Emig; Jordan S Fridman; Darren R Veach; William G Bornmann; Bayard Clarkson; W Richard McCombie; Scott C Kogan; Andreas Hochhaus; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

7.  Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.

Authors:  Hiroyuki Kawagoe; Gerard C Grosveld
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

8.  EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.

Authors:  Enrique C Torchia; Kelli Boyd; Jerold E Rehg; Chunxu Qu; Suzanne J Baker
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

9.  Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice.

Authors:  David Caudell; David P Harper; Rachel L Novak; Rachel M Pierce; Christopher Slape; Linda Wolff; Peter D Aplan
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

10.  NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.

Authors:  Ying-Wei Lin; Christopher Slape; Zhenhua Zhang; Peter D Aplan
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.